Navigation Links
Arpida's iclaprim MAA Accepted for Review by EMEA
Date:8/21/2008

REINACH, Switzerland, August 21 /PRNewswire-FirstCall/ -- Arpida Ltd. (SWX: ARPN) today announced that the European Medicines Agency (EMEA) has accepted for review its Marketing Authorisation Application (MAA) for intravenous iclaprim. Arpida is seeking approval of intravenous iclaprim in the European Union for the treatment of complicated Skin and Soft Tissue Infections (cSSTI). Iclaprim is a hospital antibiotic drug candidate with potent bactericidal (killing) activity against MRSA and an extended range of important pathogens.

The iclaprim MAA contains data from 15 clinical studies, including two well-controlled multinational pivotal Phase III trials (ASSIST-1 and ASSIST-2, in which approximately 1,000 patients were treated). Patients enrolled in the Phase III trials exhibited a high incidence of methicillin-resistant Staphylococcus aureus (MRSA) as causative pathogen. In both of these two independent Phase III trials, intravenous iclaprim achieved the pre-specified primary endpoint of non-inferiority as compared to linezolid. In the studies, iclaprim was well-tolerated with a safety profile which compared favourably with the comparator in the treatment of patients with cSSTI.

Dr Paul Hadvary, Head of Development of Arpida Ltd., commented: "Iclaprim is under regulatory review at the major health authorities on both sides of the Atlantic. We are steadily continuing our progress towards our goal of launching intravenous iclaprim, thereby providing healthcare professionals with a new option in treating serious skin infections."

In addition to the cSSTI indication, intravenous iclaprim is also being developed for the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare-associated pneumonia (HCAP) suspected or confirmed to be due to Gram-positive pathogens. This programme is currently in Phase II clinical evaluation. Moreover, an oral formulation of iclaprim is currently in a Phase
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
2. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
3. Positive Outcome of Drug-Drug Interaction Trial With Intravenous Iclaprim
4. First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP
5. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
6. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
7. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
8. Arpida Announces FDA Acceptance of the Iclaprim New Drug Application
9. Neuralstem Shares Accepted for Trading on Amex(R)
10. Nitecs IND Application for Clinical Development With Lodotra Accepted by the FDA
11. New Drug Application for Tolvaptan, Otsukas Investigational Novel Oral Treatment for Worsening Heart Failure and Hyponatremia, Accepted by the U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 23, 2014 Follow us ... steady popularity the world over, due to its ... in the marketplace is expected to come from ... developing countries. Several sub-Saharan countries in the African ... already implemented genetically engineered crop production strategies. Rising ...
(Date:9/23/2014)... , Sept. 23, 2014  Age Defying Dermatology ® ... , has become one of the first clinics in ... "picoseconds" aesthetic laser for tattoo removal. The treatment safely ... results. "For years, tattoo removal has been a lengthy, ... Noodleman. "This is an opportunity to erase tattoo pigment ...
(Date:9/23/2014)... - Portage Biotech Inc. ("Portage" or "the Company") (OTC: ... announce that its wholly owned subsidiary, Portage Pharmaceuticals ... its team for further development of its PPL-003 ... permeable peptide platform technology derived from human genes ... Ms. Holly Prentice ...
(Date:9/23/2014)... BOSTON, Mass. (PRWEB) September 23, 2014 ... driven by Semantic Web technology, was named in the ... by Gartner, Inc. , The report details key ... category. , According to Gartner analysts Michael Shanler ... help accelerate innovation activities, expose complex relationships with scientific ...
Breaking Biology Technology:Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 4Age Defy Now Offers World's Most Advanced Technology for Tattoo Removal 2Portage Announces New Consultants for its PPL-003 Development Programs 2Portage Announces New Consultants for its PPL-003 Development Programs 3Portage Announces New Consultants for its PPL-003 Development Programs 4Cambridge Semantics Identified in Gartner’s ‘Hype Cycle for Life Sciences 2014’ Report 2
... 17 PLC Systems Inc.,(AMEX: PLC ) today ... the,American Stock Exchange that would demonstrate its ability to ... that its common stock will be delisted from the ... to trade on the,over-the-counter bulletin board., As previously ...
... DNA2.0, the leading synthetic genomics company, announced today a significant ... interface, a customer-friendly site navigation, a database of published synthetic ... with a powerful resource for analyzing DNA and protein sequences. ... ...
... 17 Waters Corporation,(NYSE: WAT ) ... detection of melamine in,infant formula and liquid ... of Science and Technology (M.O.S.T.). The new ... with tandem,quadrupole mass spectrometry (UPLC/MS/MS) operated in ...
Cached Biology Technology:PLC Systems Expects Common Stock To Be Delisted From American Stock Exchange 2PLC Systems Expects Common Stock To Be Delisted From American Stock Exchange 3DNA2.0 Launches New Website: Enhanced Design and Free Bioinformatics Tools Demonstrate DNA2.0's Customer Focus 2Waters Publishes Rapid and Specific Method of Detection for Melamine in Infant Formula and Liquid Milk, in Support of China's Ministry of Science and Technology 2
(Date:9/23/2014)... Health will award funds to support the next phase ... improve ways of predicting drug safety and effectiveness. Researchers ... human tissue chips and combine them into an integrated ... human body. Led by the National Center for Advancing ... at $17 million in 2014 with additional support over ...
(Date:9/23/2014)... Foundation scientists have published a study showing that ... task-specific movement for 4 weeks can retrain the ... foot drop stimulator as rehabilitation intervention may facilitate ... of the tibialis anterior demonstrates a training effect ... published online ahead of print on July 2 ...
(Date:9/23/2014)... cow rumens and termite guts for microbes that can ... of next-generation biofuels, but some of the best microbial ... researchers report. , Their study , reported in ... , is the first to use biochemical approaches to ... can digest fiber, breaking it down into simple sugars ...
Breaking Biology News(10 mins):NIH funds next phase of Tissue Chip for Drug Screening program 2NIH funds next phase of Tissue Chip for Drug Screening program 3NIH funds next phase of Tissue Chip for Drug Screening program 4Search for better biofuels microbes leads to the human gut 2Search for better biofuels microbes leads to the human gut 3
... announces that a new market research report is available ... Industry http://www.reportlinker.com/p090669/Global-Flow-Cytometers-Industry.html ... in US$ Million. The report provides separate comprehensive analytics ... America. Annual estimates and forecasts are provided for the ...
... eye disorder characterized by progressive loss of vision that ... end stage. , In a ChIP-Seq based approach, the ... factor Crx (Cone-rod homeobox) in the expression of retina-specific ... visual perception. In-depth analysis of Crx mediated regulation in ...
... The 2010 Golf Atlanta charity golf tournament raised $105,000 in ... treatments and eventually a cure for pancreatic cancer. 2010 ... Crabapple Golf Club in Alpharetta, Ga., just north of Atlanta. ... a non-profit biomedical research facility in Phoenix, Ariz., working to ...
Cached Biology News:Reportlinker Adds Global Flow Cytometers Industry 2Reportlinker Adds Global Flow Cytometers Industry 3Reportlinker Adds Global Flow Cytometers Industry 4Reportlinker Adds Global Flow Cytometers Industry 5Reportlinker Adds Global Flow Cytometers Industry 6Reportlinker Adds Global Flow Cytometers Industry 7Reportlinker Adds Global Flow Cytometers Industry 8Reportlinker Adds Global Flow Cytometers Industry 9Transcription factor scan identifies genetic cause for inherited blindness 2Golf Atlanta charity tournament raises $105,000 for TGen research 2
... is a post-translational modification that plays ... including immune regulation, inflammation, cell-to-cell adhesion, ... developed two lectin based Glycoprotein Isolation ... Germ Agglutinin (WGA), that allow isolation ...
... Mini Trans-Blot cell and PowerPac Basic power supply ... membranes. The Mini Trans-Blot cell accommodates two 7.5 ... holder cassettes, modular electrode assembly, Bio-Ice cooling unit, ... fiber pads. The PowerPac basic power supply, 100-120 ...
... Lumat tube luminometer provides the sensitivity and ... luminometer. Advanced digital photon counting with selected ... of spectral demands. Equipped with up to ... suited for reporter gene assays as well ...
... This kit allows for rapid, convenient, and ... simple bind/wash/elute process utilizes a spin column ... beads for concentration of proteins which were ... are strong ion exchangers, offering high binding ...
Biology Products: